You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Transition to new GMP requirements for medicinal products
A notice about the implications of adopting PE009-13
|Version||Description of change||Author||Effective date|
|V1.0||Original publication||Manufacturing Quality Branch||November 2017|